PyrAmes

PyrAmes is a private, commercial-stage medical device company pioneering continuous non-invasive blood pressure (cNIBP) monitoring. Its core innovation is a wireless, calibration-free sensor technology that provides accurate, real-time blood pressure data, initially focused on the vulnerable neonatal and pediatric intensive care population with its FDA 510(k)-cleared Boppli® platform. The company is now developing its technology for adult inpatient (Bosimi®) and home diagnostic (Bosimi@Home™) markets, targeting a massive global need driven by hypertension and critical care monitoring gaps. Backed by recognition from the NIH, AHA, and FDA Breakthrough Device designation, PyrAmes is positioned to transform a foundational vital sign measurement.

Proprietary wireless biosensor technology for calibration-free, continuous non-invasive blood pressure (cNIBP) monitoring. Adaptable platform for neonatal, adult inpatient, and home use.

In neonatal cNIBP, PyrAmes appears to be a pioneer with its FDA-cleared Boppli® system. In the broader cNIBP space, it faces competition from companies like Edwards Lifesciences (ClearSight) and others developing non-invasive hemodynamic monitors. For the home market, it will compete with traditional cuff manufacturers and emerging wearable tech companies. Its key differentiators are its calibration-free operation, wireless design, and platform approach across patient ages.